PURPOSE: Glioblastoma (GBM) patients have many palliative care (PC) issues. To date, there are no studies examining the prospective usage of validated PC assessment tools as patient reported outcome measures for GBM patients. METHODS: GBM patients' PC issues were assessed from diagnosis to death or for at least 12 months every 7 weeks (±8 days) using semi-structured interviews and the Hospice and Palliative Care Evaluation (HOPE, including Eastern Cooperative Oncology Group (ECOG) performance status, 17 items) and the Palliative Outcome Scale (POS, 11 items). Data from patients who died within 12 months of the last patient's enrollment were evaluated using summarizing content analysis, visual graphical analysis (VGA), and linear mixed models for repeated measures. RESULTS: Nineteen of 33 patients screened were enrolled; two dropped out and four were still alive at the end of the study. The remaining 13 were assessed at 59 points until death (time range 4-68 weeks; 1-10 contacts per patient; assessment: self, 33; joint, 8; external, 18). VGA of the HOPE and POS data, including all 1,652 assessed item data, showed consistent trajectory profiles for 14 of 28 items: 10 were increasing (meaning symptom worsening) and comprised predominantly psychosocial issues and care dependency. Type of assessment partly interacted with time, however, not qualitatively so. Analysis of semi-structured interviews revealed delayed interactions with PC/hospice services and numerous neuropsychiatric problems not detected by HOPE and POS. CONCLUSIONS: Prospective self-assessment of GBM patients' PC issues is feasible. However, disease progression may necessitate further, external assessment. Modification of existing PC assessment tools is needed to detect GBM-specific issues.
PURPOSE:Glioblastoma (GBM) patients have many palliative care (PC) issues. To date, there are no studies examining the prospective usage of validated PC assessment tools as patient reported outcome measures for GBM patients. METHODS: GBM patients' PC issues were assessed from diagnosis to death or for at least 12 months every 7 weeks (±8 days) using semi-structured interviews and the Hospice and Palliative Care Evaluation (HOPE, including Eastern Cooperative Oncology Group (ECOG) performance status, 17 items) and the Palliative Outcome Scale (POS, 11 items). Data from patients who died within 12 months of the last patient's enrollment were evaluated using summarizing content analysis, visual graphical analysis (VGA), and linear mixed models for repeated measures. RESULTS: Nineteen of 33 patients screened were enrolled; two dropped out and four were still alive at the end of the study. The remaining 13 were assessed at 59 points until death (time range 4-68 weeks; 1-10 contacts per patient; assessment: self, 33; joint, 8; external, 18). VGA of the HOPE and POS data, including all 1,652 assessed item data, showed consistent trajectory profiles for 14 of 28 items: 10 were increasing (meaning symptom worsening) and comprised predominantly psychosocial issues and care dependency. Type of assessment partly interacted with time, however, not qualitatively so. Analysis of semi-structured interviews revealed delayed interactions with PC/hospice services and numerous neuropsychiatric problems not detected by HOPE and POS. CONCLUSIONS: Prospective self-assessment of GBM patients' PC issues is feasible. However, disease progression may necessitate further, external assessment. Modification of existing PC assessment tools is needed to detect GBM-specific issues.
Authors: Stefan Oberndorfer; Elisabeth Lindeck-Pozza; Heinz Lahrmann; Walter Struhal; Peter Hitzenberger; Wolfgang Grisold Journal: J Palliat Med Date: 2008 Jan-Feb Impact factor: 2.947
Authors: Debbie Cavers; Belinda Hacking; Sara E Erridge; Marilyn Kendall; Paul G Morris; Scott A Murray Journal: CMAJ Date: 2012-03-19 Impact factor: 8.262
Authors: Matthias Seibl-Leven; Christian von Reeken; Roland Goldbrunner; Stefan Grau; Maximilian Ingolf Ruge; Norbert Galldiks; Veronika Dunkl; Martin Kocher; Raymond Voltz; Heidrun Golla Journal: J Neurooncol Date: 2018-02-20 Impact factor: 4.130
Authors: Anthony Byrne; Anna Torrens-Burton; Stephanie Sivell; Fabio Ynoe Moraes; Helen Bulbeck; Mark Bernstein; Annmarie Nelson; Helen Fielding Journal: Cochrane Database Syst Rev Date: 2022-01-06
Authors: Erqi L Pollom; Katherine D Sborov; Scott G Soltys; Steven M Asch; Rebecca L Sudore; Rebecca A Aslakson Journal: J Pain Symptom Manage Date: 2018-09-07 Impact factor: 3.612
Authors: Markus Ebke; Andreas Koch; Kim Dillen; Ingrid Becker; Raymond Voltz; Heidrun Golla Journal: Front Neurol Date: 2018-09-24 Impact factor: 4.003
Authors: Joshua D Palmer; Gordon Chavez; Wesley Furnback; Po-Ya Chuang; Bruce Wang; Christina Proescholdt; Chao-Hsiun Tang Journal: Front Oncol Date: 2021-12-02 Impact factor: 6.244